Viral kinetic and Pharmacodynamic Parameters and IL28B Polymorphism
The maximum PEG-IFN effectiveness during the first week of therapy, ϵ7max, the average PEG-IFN effectiveness during the first week of therapy, ϵ7average, and the maximum PEG-IFN effectiveness from week 4 to week 12 of therapy, ϵmax, were significantly (P = 0.008, 0.008, and 0.044, respectively) higher in genotype-CC [median (IQR) 94% (11%), 92% (13%), and 96% (6%), respectively] than in patients with genotype-TC/TT [81% (45%), 77% (45%), and 87% (33%), respectively; Table 1]. The PEG-IFN concentration at which the PEG-IFN-α-2a effectiveness in blocking viral production is half its maximum, EC50, was significantly (P = 0.02) lower in genotype-CC [median (IQR) 1.3(1.8)] than in genotype-TC or TT [3.3(11.5)]. When the analysis was confined to HCV genotype-1 cases, EC50 was lower (but not significant, P = 0.6) in genotype-CC, but there was a trend toward a correlation between genotype-CC and both ϵ7average and δ (P = 0.11, Table 1). In contrast, in HCV-genotype-3 patients, there were trends toward higher ϵ7average and lower EC50 (P = 0.1) with genotype-CC, whereas an association was less evident for δ (P = 0.7, Table 1) among IL28B genotypes.
A detailed HCV kinetic analysis provided new and important information regarding the impact of IL28B genotype on response to PEG-IFN plus RBV in HIV/HCV-coinfected patients. Overall, the CC-genotype was most strongly associated with a higher first-phase viral decline and maximum PEG-IFN effectiveness during the first week of therapy, ϵ7max. These findings indicate that PEG-IFN has greater efficacy in blocking HCV production/release in patients with the favorable IL28B CC-genotype. Our results are in agreement with recent findings in HCV-monoinfected patients.14,15 The PEG-IFN-α-2a EC50 was lower in genotype-CC compared with genotype-TC/TT, providing further evidence that the CC-genotype confers a higher sensitivity to IFN treatment. Thus far, the mechanism of action of the IL28B polymorphism has not been identified. The location of the genetic polymorphism upstream of the IFN-λ gene18,19 raises the possibility that the IL28B genotype mediates endogenous production of IFN-λ, which contributes to the first-phase response by stimulating IFN signaling.
The second-phase viral decline slope also was associated with genotype-CC in genotype 1 patients (Table 1). The overall correlation between the CC-genotype and the infection death/loss rate, δ, was less prominent (trend, P = 0.11). This discrepancy could be explained by the fact that 6 of 21 of patients who finished 48 weeks of therapy in our study17 had a triphasic viral decline pattern consisting of a first phase (1-2 days) with a rapid virus load decline followed by a “shoulder phase” (8-28 days), in which virus levels decay slowly or remain constant, and a third phase of renewed viral decay.20,21 Calculating the slower phase slope from the measured data includes the “shoulder phase” in these triphasic patients. In contrast, by using a mathematical model that includes hepatocytes proliferation, estimated δ reflects the final slope and excludes the shoulder phase.22 Interestingly, 5 of the 6 triphasic patients had genotype-TT/TC and only 1 had genotype-CC (not shown). In addition, we recently showed that drug effectiveness, ϵ, can significantly affect the serum second-phase slope decline,22 and that when ϵ∼1 the slower phase slope is close to δ. Indeed, when the analysis was performed only in patients with first-phase decline >1 log (ie, ϵ > 90%), the association between IL28B genotype-CC and the slower phase slope was lost (P = 0.5, not shown), in agreement with recent results in HCV-monoinfected patients.15 Thus, although the slower phase slope, and as a consequence RVR rates, are correlated with the IL28B genotype, the driving effect is the difference in the IFN antiviral effectiveness in blocking virion production (first-phase decline). The data suggest that the IL28B polymorphism has less of an effect on the infected-cell-loss rate that has been attributed to immune mediated clearance of infected cells.23
Among viral response parameters, we found that RVR and cEVR rates are significantly associated with genotype-CC (see Table 1, Supplemental Digital Content 1, http://links.lww.com/QAI/A112), in agreement with recent results in HCV (genotypes 1/2/3)-monoinfected patients.15,24 Among HCV genotype-1 subjects in our study, 10 subjects (of 11) who had genotype CT/TT failed to achieve an SVR in agreement with the strong association recently shown in larger HIV/HCV-coinfected cohorts by Rallon et al25 and Pineda et al.26 However, the weak association between genotype-CC and SVR (P = 0.3; see Table 1, Supplemental Digital Content 1, http://links.lww.com/QAI/A112) in HCV genotype-1-infected subjects in our study may be related to the small sample size and to the discontinuation of 5 patients at week 12 of therapy as previously explained.17 The faster first and second-phase viral declines observed in IL28B genotype-1-CC patients and the higher first-phase viral decline in genotype-3-CC patients provide evidence that the IL28B genotype favorably impacts on viral kinetics.
Evaluation of baseline characteristics showed genotype-CC subjects had a higher body weight. Larger studies are needed to evaluate whether genotype CC might overcome the deleterious impact of higher body weight on SVR. In addition, there was a significantly higher proportion of IL28B genotype-CC in patients infected with HCV-genotype 3 than in patients infected with HCV-genotype 1 (see Table 1, Supplemental Digital Content 1, http://links.lww.com/QAI/A112), in agreement with recent studies that include HIV/HCV-coinfected25 and HCV-monoinfected individuals.27 We previously reported higher first and faster second-phase viral declines in genotype-3 compared with genotype-1 HIV/HCV-coinfected patients.16 In the current study, we identified a higher prevalence of IL28B CC-genotype in HCV genotype-3 cases, but no association between IL28B genotype and the second-phase viral decline or the loss rate of HCV-infected cells, δ in HCV genotype-3. Because the second slope phase and/or δ correlate with the outcome of therapy,23 these findings suggest that the relatively rapid second-phase viral decline in genotype-3 patients is related to factors other than the genetic polymorphism. Our observations might explain the lack of association between IL28B genotype and SVR in genotype-3 patients recently reported by Rallon et al.25 In contrast, higher ϵ7average and δ were associated (trend, P = 0.1) with CC-genotype in HCV genotype-1-infected patients. The trends observed in genotype-1 patients may reflect the small sample size and is anticipated to be significant in larger studies.
Previous studies of HCV-monoinfected patients conducted in the United States reported a higher proportion of IL28B genotype-TC/TT in African Americans than in non-Hispanic white.10,14 In contrast, we did not identify a significant (P = 0.5) difference in IL28B genotype frequencies between African Americans and white patients from Brazil (Table 1). The lack of an association between race and IL28B genotype in our South American patient population might partly explain the lack of association between race/ethnicity and viral kinetic parameters or viral response patterns in our recent reports.16,17 Indeed, preliminary results indicate that ∼80% (of 500) of HCV-monoinfected individuals in Brazil are TC or TT with a similar distribution of CC/TC/TT genotypes between African Americans and whites.28 Larger studies are needed to provide a comprehensive evaluation of IL28B genotypes and viral kinetics by race/ethnicity in South America, where patient ancestry may differ from that in the United States.
In conclusion, in HIV/HCV-coinfected patients, the IL28B-CC genotype was most strongly associated with a higher first-phase viral decline and greater average PEG-IFN effectiveness during the first week of therapy, ϵ7max. Pharmacodynamic analysis showed that genotype-CC conferred increased sensitivity to PEG-IFN, as shown by a lower PEG-IFN-α-2a EC50. These kinetic findings raise the possibility that the IL28B CC-genotype favorably affects viral response by augmenting IFN-λ-mediated activation of the IFN signaling cascade, leading to increased effectiveness in blocking virion production/release. Notably, as we approach a new era of combination therapy with PEG-IFN and direct antiviral agents, a better understanding of factors associated with PEG-IFN-related viral kinetics will provide the basis to develop optimal treatment strategies for HCV.29,30 Larger and more detailed studies are needed to confirm these new observations in HIV/HCV-coinfected patients.
The authors thank Steve Young from Tricore Reference Laboratories for performing HIV and HCV load tests; LIM-47 team for excellent technical assistance; Fernando F. Tatsch and Lorin Brisbin from Roche for supplying drugs and tests; and the patients and their family members for the trust and participation.
1. Arends JE, Boucher CA, Hoepelman AI. Hepatitis C virus and human immunodeficiency virus coinfection: where do we stand? Neth J Med
2. Ferreira P, Navarro R. Coinfeccção VHC/HIV, VHB/VHC/HIV, VHC/HTLV. In: Hepatite C
. 1st ed. São Paulo Manole Editing; 2010: 280-308.
3. Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med
4. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med
5. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA
6. Ballesteros AL, Franco S, Fuster D, et al. Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. AIDS
7. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet
8. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med
9. Thomas DL. Options for treatment of hepatitis C in HIV-infected persons. J Hepatol
. 2006;44(1 suppl):S40-S43.
10. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature
11. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet
12. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet
13. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology
. 2010 Jul;139(1):120-9.
14. Howell CD, Thompson AJ, Ryan K, et al. IL28B genetic variation association with early viral kinetics and SVR in HCV henotype 1 the VIRAHEP-C study. J Hepatol
. 2010;52(Suppl 1):S451.
15. Neumann AU, Bibert S, Haagmans B, et al. IL28B polymorphism is significantly correlated with IFN anti-viral effectivness already on first day of pegylated interferon-α and ribavirin therapy of chronic HCV infection J Hepatol
. 2010;52(Suppl 1):S468.
16. Araujo ESA, Dahari H, Neumann AU, et al. Very early prediction of response to HCV treatment with peg-IFN-alfa-2a and ribavirin in HIV/HCV coinfected patients. J Viral Hepat
. 2010. In press.
17. Dahari H, Araujo E, Haagmans B, et al. Pharmacodynamics of PEG-IFN alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. J Hepatol
18. Thio CL, Thomas DL. Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle. Gastroenterology
19. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology
. 2010;138:1338-1345, e1331-e1337.
20. Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology
21. Herrmann E, Lee JH, Marinos G, et al. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology
22. Dahari H, Shudo E, Cotler SJ, et al. Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay. Antivir Ther
23. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science
24. Mangia A, Thompson AJ, Santoro R, et al. Interleukin-28B polymorphism determines treatment response of patients with hepatitis C genotypes 2 or 3 who do not achieve a rapid virologic response. Gastroenterology
25. Rallon NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS
26. Pineda JA, Caruz A, Rivero A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis
27. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology
28. Araujo ESA, Melo CE, Martins LP et al. Brazilian profile of IL28-B single nucleotide polymorphism (SNP): a retrospective analysis and possible consequences for interferon-alpha based therapies. Hepatology
29. Zeuzem S, Nelson DR, Marcellin P. Dynamic evolution of therapy for chronic hepatitis C: how will novel agents be incorporated into the standard of care? Antivir Ther
30. Boehme RE, Cameron S. Key data from the 11th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV. Antivir Ther
Mathematical modeling; viral kinetics; pharmacodynamics; HCV; HIV; IL28B; pegylated interferon alpha-2a
Supplemental Digital Content
© 2011 Lippincott Williams & Wilkins, Inc.